Drug Topics

JANUARY 30, 2025

Joseph DiPiro, PharmD, FCCP, FAAAS, broke down the importance of the ASHP Pharmacy Forecast and the process in which its content is curated.

247

247

PharmaVoice

JANUARY 27, 2025

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

279

279

STAT

JANUARY 29, 2025

Curie.Bio, the biotech accelerator and investment firm started by Alexis Borisy and Zach Weinberg, has raised another $340 million to invest in startups. Borisy and Weinberg’s firm was created to upend the biotech financing model , offering both capital and expert assistance to founders seeking on option outside of traditional VC funding. The idea has resonated with venture capitalists — several of whom have invested in Curie.Bio — and startups.

113

113

Pharmacy Times

JANUARY 30, 2025

The drug is a selective NaV1.8 pain signal inhibitor and is the first new class of medication to treat acute pain in over 20 years.

FDA 165

FDA 165

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JANUARY 30, 2025

A survey conducted by 3 Axis Advisors revealed potential impacts of the Inflation Reduction Acts Medicare Drug Price Negotiation Program.

Community Pharmacies 570

Community Pharmacies 570

PharmaVoice

JANUARY 27, 2025

These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.

Immunization 182

Immunization 182

Pharmacy Times

JANUARY 28, 2025

The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with these chronic conditions.

FDA 157

FDA 157

Drug Topics

JANUARY 25, 2025

Among a population of patients with type 2 diabetes, researchers assessed the similarities and differences between SGLT2 inhibitors.

467

467

PharmaVoice

JANUARY 28, 2025

As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.

162

162

Pharmafile

JANUARY 29, 2025

Beckley Psytech Ltd, a clinical-stage biopharmaceutical company that specialises in the production of accessible medicines for mental health conditions, has announced positive results for the phase 2a study into BPL-003 in patients with moderate-to-severe Alcohol Use Disorder (AUD). The study, labelled NCT05674929, was conducted at Kings College London and Clerkenwell Health, both UK.

Labelling 64

Labelling 64

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JANUARY 30, 2025

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

153

153

Drug Topics

JANUARY 31, 2025

There is no standard way to define resilience in adolescent patients with type 1 diabetes, though many studies see resilience as an ability or process.

371

371

PharmaVoice

JANUARY 31, 2025

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation.

147

147

Fierce Healthcare

JANUARY 28, 2025

Chief among the questions raised by Monday's ambiguous memo are whether programs like Medicaid and SNAP as well as funding for clinical research, community health centers, suicide prevention and state infectious disease surveillance will see interruptions due to the pause.

142

142

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

The Guardian - Pharmaceutical Industry

JANUARY 26, 2025

Current rules leave door open for medicines to be supplied without appropriate patient consultation, association says Pharmacies are demanding tougher regulation of the online sale of weight-loss jabs amid a predicted new years boom in demand. The National Pharmacy Association (NPA), who represent independent community pharmacies, urged the regulator to require greater consultation with patients before dispensing weight-loss jabs and other high-risk medication online.

Community Pharmacies 57

Community Pharmacies 57

Drug Topics

JANUARY 29, 2025

Scott Nelson, PharmD, MS, FAMIA, ACHIP, discussed the increasingly crucial role artificial intelligence has played in streamlining pharmacy services.

315

315

PharmaVoice

JANUARY 29, 2025

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

147

147

European Pharmaceutical Review

JANUARY 29, 2025

Researchers have developed and optimised a novel sensing strategy for isomer discrimination by combining advanced spectroscopy with machine learning. The approach is based on surface-enhanced Raman scattering (SERS) substrates (ie, plasmonic platforms). Montes-Garca et al. explained that they fabricated advanced SERS substrates made of quasi-spherical gold nanoparticles (Au NPs) synthesised via a seeded growth method.

59

59

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JANUARY 28, 2025

Endocrine therapy in combination with CDK4/6 inhibitors improves patients outcomes, but many still become treatment resistant.

139

139

Drug Topics

JANUARY 30, 2025

Adolescent obesity rates have risen in recent years, and a number of treatment options can be taken to help reduce the risk of a variety of associated medical problems.

281

281

PharmaVoice

JANUARY 29, 2025

Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

FDA 147

FDA 147

STAT

JANUARY 29, 2025

My son was 5 years old when he climbed out of bed and landed on the floor. He was always a teaser. “C’mon, silly,” I said. “Time to get ready for school.” “Mommy,” Aaron said, very puzzled. “I can’t feel my legs.

Vaccines 135

Vaccines 135

Pharmacy Times

JANUARY 30, 2025

Children and adults with cancer have differing immune system responses, mutational burdens, and tissue microenvironments.

Immunization 137

Immunization 137

Drug Topics

JANUARY 31, 2025

Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.

FDA 247

FDA 247

The FDA Law Blog

JANUARY 29, 2025

By John W.M. Claud & JP Ellison The confirmation hearings for Robert F. Kennedy, Jr. to lead the Department of Health and Human Services promise to have a packed agenda. With oversight over FDA, the Centers for Medicare & Medicaid Services, the National Institutes of Health, and the Centers for Disease Control and Prevention, Kennedys portfolio will be vast.

FDA 59

FDA Vaccines 59

Fierce Healthcare

JANUARY 30, 2025

Sen. Bill Cassidy, chair of the Senate HELP Committee, and ranking member Bernie Sanders were aligned on their concerns about Kennedy's approach to vaccines. With a vote on Kennedys nomination to take place in the Senate Finance Committee next week, Cassidy, who also sits on that committee, said hes going to have to use the weekend to make up his mind.

Vaccines 132

Vaccines 132

Pharmacy Times

JANUARY 27, 2025

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

FDA 133

FDA 133

Drug Topics

JANUARY 31, 2025

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

FDA 247

FDA 247

PharmaVoice

JANUARY 30, 2025

“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.

Vaccines 130

Vaccines 130

Pharmafile

JANUARY 29, 2025

Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence (NICE) for AGAMREE (vamorolone) to be used as treatment of Duchenne Muscular Dystrophy (DMD) in patients who are aged 4 or older in the UK. The guidance follows the approval of vamorolone from the Medicines and products Regulatory Agency (MHRA) […] The post NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera appeared first on Pharmafil

FDA 59

FDA 59

Pharmacy Times

JANUARY 31, 2025

The approval includes indications for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.

FDA 127

FDA 127

Drug Topics

JANUARY 30, 2025

The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.

FDA 247

FDA 247

Fierce Healthcare

JANUARY 28, 2025

The National Community Pharmacists Association is warning the feds that independent pharmacists are likely to face significant financial hardship due to Medicare drug price negotiations.

127

127